Selection bias, phase II trials, and the FDA accelerated approval process

J Natl Cancer Inst. 2003 Sep 17;95(18):1351-2. doi: 10.1093/jnci/djg070.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Carcinoma, Non-Small-Cell Lung / drug therapy
  • Clinical Trials, Phase II as Topic / standards*
  • Drug Approval*
  • Gefitinib
  • Humans
  • Lung Neoplasms / drug therapy
  • Neoplasms / drug therapy*
  • Quinazolines / therapeutic use
  • Selection Bias*
  • Treatment Outcome
  • United States
  • United States Food and Drug Administration

Substances

  • Antineoplastic Agents
  • Quinazolines
  • Gefitinib